Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha

Laboratory Investigation

Volumn 86, Issue 4, 2006, Pages 345-356

  Groot, Arjan J ^a   Verheesen, Peter ^b   Westerlaken, Elike J ^a   Gort, Eelke H ^a   Van Der Groep, Petra ^a   Bovenschen, Niels ^a   Van Der Wall, Elsken ^a   Van Diest, Paul J ^a   Shvarts, Avi ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cancer; Hetero bivalent VHH; HIF 1 ; Hypoxia; Phage display; Single domain antibody fragment; VHH

Indexed keywords

EPITOPE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PROTEIN ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; BINDING, COMPETITIVE; CAMELIDS, NEW WORLD; CLONING, MOLECULAR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 33645279790     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700395     Document Type: Article

References (43)

1. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-578.
2. Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 2005;242:157-213.
3. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-4015.
4. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-1480.
5. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000;14:1983-1991.
6. Brahimi-Horn C, Pouyssegur J. When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy. Crit Rev Oncol Hematol 2005;53:115-123.
7. Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther 2004;3:608-611.
8. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004;3:647-654.
9. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 2003;3:391-405.
10. Park JW, Chun YS, Kim MS. Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci 2004;94:221-232.
11. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-314.
12. Greijer AE, de Jong MC, Scheffer GL, et al. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 2005;27:43-49.
13. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-1581.
14. Vleugel MM, Greijer AE, Shvarts A, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 2005;58:172-177.
15. Dales JP, Garcia S, Meunier-Carpentier S, et al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-739.
16. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-448.
17. Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002;11:500-515.
18. Muyldermans S. Single domain camel antibodies: current status. J Biotechnol 2001;74:277-302.
19. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004;64:2853-2857.
20. van der Linden RH, Frenken LG, de Geus B, et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1999;1431:37-46.
21. Perez JM, Renisio JG, Prompers JJ, et al. Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry 2001;40:74-83.
22. Dolk E, van der Vaart M, Lutje Hulsik D, et al. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol 2005;71:442-450.
23. Dekker S, Toussaint W, Panayotou G, et al. Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses. J Virol 2003;77:12132-12139.
24. Desmyter A, Spinelli S, Payan F, et al. Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology. J Biol Chem 2002;277:23645-23650.
25. Muruganandam A, Tanha J, Narang S, et al. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 2002;16:240-242.
26. Gothie E, Richard DE, Berra E, et al. Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J Biol Chem 2000;275:6922-6927.
27. Lee JW, Bae SH, Jeong JW, et al. Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions. Exp Mol Med 2004;36:1-12.
28. 2-regulated prolyl hydroxylation. Science 2001;292:468-472.
29. 2 sensing. Science 2001;292:464-468.
30. Els Conrath K, Lauwereys M, Wyns L, et al. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001;276:7346-7350.
31. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002;98:456-462.
32. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613.
33. Chachami G, Paraskeva E, Georgatsou E, et al. Bacterially produced human HIF-1alpha is competent for heterodimerization and specific DNA-binding. Biochem Biophys Res Commun 2005;331:464-470.
34. Frenken LG, van der Linden RH, Hermans PW, et al. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 2000;78:11-21.
35. Huang Y, Verheesen P, Roussis A, et al. Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. Eur J Hum Genet 2005;13:721-730.
36. van Koningsbruggen S, de Haard H, de Kievit P, et al. Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy. J Immunol Methods 2003;279:149-161.
37. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993;82:3610-3615.
38. Spinelli S, Frenken LG, Hermans P, et al. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 2000;39:1217-1222.
39. Kabat E, Wu TT, Perry H, et al. Sequences of Proteins of Immunological Interest. US Department of Health and Human Service: Bethesda, 1991.
40. Ditzel HJ, Binley JM, Moore JP, et al. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J Immunol 1995;154:893-906.
41. Sanna PP, Williamson RA, De Logu A, et al. Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries. Proc Natl Acad Sci USA 1995;92:6439-6443.
42. Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002;111:709-720.
43. Verheesen P, de Kluijver A, van Koningsbruggen S, et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear poly(A)-binding protein with a single-domain intracellular antibody. Hum Mol Genet 2006;15:105-111.